TY - JOUR
T1 - 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis
T2 - An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
AU - Rider, Lisa G.
AU - Aggarwal, Rohit
AU - Pistorio, Angela
AU - Bayat, Nastaran
AU - Erman, Brian
AU - Feldman, Brian M.
AU - Huber, Adam M.
AU - Cimaz, Rolando
AU - Cuttica, Rubén J.
AU - de Oliveira, Sheila Knupp
AU - Lindsley, Carol B.
AU - Pilkington, Clarissa A.
AU - Punaro, Marilynn
AU - Ravelli, Angelo
AU - Reed, Ann M.
AU - Rouster-Stevens, Kelly
AU - van Royen-Kerkhof, Annet
AU - Dressler, Frank
AU - Magalhaes, Claudia Saad
AU - Constantin, Tamás
AU - Davidson, Joyce E.
AU - Magnusson, Bo
AU - Russo, Ricardo
AU - Villa, Luca
AU - Rinaldi, Mariangela
AU - Rockette, Howard
AU - Lachenbruch, Peter A.
AU - Miller, Frederick W.
AU - Vencovsky, Jiri
AU - Ruperto, Nicolino
AU - Rider, Lisa G.
AU - Ruperto, Nicolino
AU - Miller, Frederick W.
AU - Vencovsky, Jiri
AU - Aggarwal, Rohit
AU - Erman, Brian
AU - Bayat, Nastaran
AU - Pistorio, Angela
AU - Huber, Adam M.
AU - Feldman, Brian M.
AU - Hansen, Paul
AU - Rockette, Howard
AU - Lachenbruch, Peter A.
AU - Ruperto, Nicolino
AU - Rider, Lisa G.
AU - Apaz, Maria
AU - Bowyer, Suzanne
AU - Cimaz, Rolando
AU - Constantin, Tamás
AU - Maillard, Susan
AU - for the International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation
N1 - Publisher Copyright:
© 2017, American College of Rheumatology
PY - 2017/5
Y1 - 2017/5
N2 - Objective: To develop response criteria for juvenile dermatomyositis (DM). Methods: We analyzed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. Results: Consensus was reached for a conjoint analysis–based continuous model with a total improvement score of 0–100, using absolute percent change in core set measures of minimal (≥30), moderate (≥45), and major (≥70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91–98% for minimal improvement, 92–94% and 94–99% for moderate improvement, and 91–98% and 85–86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (P = 0.009–0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (P < 0.006). Conclusion: The response criteria for juvenile DM consisted of a conjoint analysis–based model using a continuous improvement score based on absolute percent change in core set measures, with thresholds for minimal, moderate, and major improvement.
AB - Objective: To develop response criteria for juvenile dermatomyositis (DM). Methods: We analyzed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. Results: Consensus was reached for a conjoint analysis–based continuous model with a total improvement score of 0–100, using absolute percent change in core set measures of minimal (≥30), moderate (≥45), and major (≥70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91–98% for minimal improvement, 92–94% and 94–99% for moderate improvement, and 91–98% and 85–86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (P = 0.009–0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (P < 0.006). Conclusion: The response criteria for juvenile DM consisted of a conjoint analysis–based model using a continuous improvement score based on absolute percent change in core set measures, with thresholds for minimal, moderate, and major improvement.
UR - http://www.scopus.com/inward/record.url?scp=85017506720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017506720&partnerID=8YFLogxK
U2 - 10.1002/art.40060
DO - 10.1002/art.40060
M3 - Article
C2 - 28382778
AN - SCOPUS:85017506720
SN - 2326-5191
VL - 69
SP - 911
EP - 923
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 5
ER -